儿童和青少年慢性髓性白血病急变期的管理:国际儿童CML专家小组建议
国际儿童CML专家小组基于当前文献和国家标准制定建议,涵盖初诊与治疗监测、与费城染色体阳性急性白血病的鉴别、亚型特异性诱导治疗选择、与TKI联合、移植时机与供者选择、预处理方案与GVHD预防、移植后TKI治疗及分子学复发管理。
要点
- 建议涵盖儿童CML急变期的初诊、治疗监测及与Ph阳性急性白血病的鉴别。
- 诱导治疗按亚型选择,并与酪氨酸激酶抑制剂联合。
- 异基因造血干细胞移植目前仍是CML急变期的主要治愈手段,建议涵盖移植时机、供者与移植物选择、预处理及GVHD预防、移植后TKI治疗和分子学复发管理。
核心结论
- 国际儿童CML专家小组基于当前文献和国家标准提出儿童和青少年CML急变期的治疗建议,旨在为未来前瞻性临床试验的设计提供基础,以改善这一高危疾病的结局。
研究设计与样本
- 由国际儿童CML专家小组制定建议,依据当前文献和国家标准。
主要发现
- 儿童和青少年CML急变期的治疗策略大多为经验性演变而来,包括源自成人CML急变期和儿童急性白血病的治疗原则。
关键数值与推荐
- 建议包括初诊与治疗监测的详细信息、与费城染色体阳性急性白血病的鉴别、亚型特异性诱导治疗选择以及与酪氨酸激酶抑制剂的联合。
- 异基因造血干细胞移植目前仍是CML急变期的主要治愈干预,建议涵盖移植时机、供者和移植物选择、预处理方案选择、移植物抗宿主病预防、移植后TKI治疗以及分子学复发的管理。
临床怎么用
- 按本建议进行管理旨在为未来前瞻性临床试验的设计提供基础,以改善这一挑战性疾病的结局。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Treatment of chronic myeloid leukemia has improved significantly with the introduction of tyrosine kinase inhibitors (TKIs), and treatment guidelines based on numerous clinical trials are available for chronic phase disease. However for CML in the blast phase (CML-BP), prognosis remains poor and treatment options are much more limited. The spectrum of treatment strategies for children and adolescents with CML-BP has largely evolved empirically and includes treatment principles derived from adult CML-BP and pediatric acute leukemia. Given this heterogeneity of treatment approaches, we formed an international panel of pediatric CML experts to develop recommendations for consistent therapy in children and adolescents with this high-risk disease based on the current literature and national standards. Recommendations include detailed information on initial diagnosis and treatment monitoring, differentiation from Philadelphia-positive acute leukemia, subtype-specific selection of induction therapy, and combination with tyrosine kinase inhibitors. Given that allogeneic hematopoietic stem cell transplantation currently remains the primary curative intervention for CML-BP, we also provide recommendations for the timing of transplantation, donor and graft selection, selection of a conditioning regimen and prophylaxis for graft-versus-host disease, post-transplant TKI therapy, and management of molecular relapse. Management according to the treatment recommendations presented here is intended to provide the basis for the design of future prospective clinical trials to improve outcomes for this challenging disease.
引用
- Sembill S, Ampatzidou M, Chaudhury S, et al. Management of children and adolescents with chronic myeloid leukemia in blast phase: International pediatric CML expert panel recommendations. Leukemia. 2023. PMID: 36707619. doi:10.1038/s41375-023-01822-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。